Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

NCT00369434 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Menopause
Vasomotor System

Interventions

DRUG: Desvenlafaxine succinate sustained-release (DVS SR)

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer